NEW YORK, February 12 -- Centagenetix and Elixir Pharmaceuticals today announced the completion of a merger initiated in January and a $17 million injection of venture capital.
The new company, called Elixir Pharmaceuticals, will be based in Cambridge, Mass., and led by Edward Cannon, president and CEO. The merger was an all-stock transaction.
Elixir is creating a technology platform for drug discovery targeting aging in laboratory organisms, while Centagenetix has a portfolio of population association studies of genes and gene variants from individuals of extreme longevity and vitality.
The new company will receive venture funding through the initial closing of a $17 million Series B round of financing led by MPM Capital of Boston, LP Arch Venture Partners of Chicago, and Oxford Bioscience Partners of Boston.